PonyWang Relay Therapeutics ( NASDAQ: RLAY ) will work with Pfizer ( PFE ) to investigation a combination of the former's RLY-2608 + fulvestrant and the latter's atirmociclib for HR+, HER2- breast cancer. RLY-2608 is a PI3Kα inhibitor while atirmociclib is a selective-CDK4 inhibitor. Terms call for Pfizer to provide atirmociclib while Relay will be responsible for conducting the study, which is expected to begin by the end of the year.
More on Pfizer, Relay Therapeutics Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) The Prognosis For Pfizer Relay Therapeutics upgraded by Barclays ahead of data readout Relay Therapeutics: Platform More Important Than Programs.
